Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Demerger Expected To Aid External Collaborations

Executive Summary

Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.

You may also be interested in...

Novo Nordisk Licenses ZymoGenetics' IP, Antibody

Novo pays $25 million up front for a pre-clinical IL-21 antibody and global IP rights to blocking IL-21.

Novo's NovoSeven Posts $19 Mil. In U.S. Sales Since April Launch

Novo Nordisk's hemophilia treatment NovoSeven (recombinant Factor VIIa) generated U.S. sales of approximately $19 mil. in its first three months on the U.S. market, Novo indicated in an Aug. 11 statement on half-year financial results. Novo began marketing the product in the U.S. in April.

Novo's NovoRapid Has 10-20 Min. Onset Of Action - EU Labeling

Novo Nordisk's diabetes mellitus treatment insulin aspart has an onset of action time of 10 to 20 minutes, according to European draft labeling for the human insulin analogue.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts